A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.

Demétrio de Souza França, Paula; Kossatz, Susanne; Brand, Christian; Karassawa Zanoni, Daniella; Roberts, Sheryl; Guru, Navjot; Adilbay, Dauren; Mauguen, Audrey; Valero Mayor, Cristina; Weber, Wolfgang A; Schöder, Heiko; Ghossein, Ronald A; Ganly, Ian; Patel, Snehal G; Reiner, Thomas

doi:10.1007/s00259-021-05372-6

journal article

Titel:: A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
Dokumenttyp:: Journal Article
Autor(en):: Demétrio de Souza França, Paula; Kossatz, Susanne; Brand, Christian; Karassawa Zanoni, Daniella; Roberts, Sheryl; Guru, Navjot; Adilbay, Dauren; Mauguen, Audrey; Valero Mayor, Cristina; Weber, Wolfgang A; Schöder, Heiko; Ghossein, Ronald A; Ganly, Ian; Patel, Snehal G; Reiner, Thomas
Abstract:: BACKGROUND: Visual inspection and biopsy is the current standard of care for oral cancer diagnosis, but is subject to misinterpretation and consequently to misdiagnosis. Topically applied PARPi-FL is a molecularly specific, fluorescent contrast-based approach that may fulfill the unmet need for a simple, in vivo, non-invasive, cost-effective, point-of-care method for the early diagnosis of oral cancer. Here, we present results from a phase I safety and feasibility study on fluorescent, topically applied PARPi-FL. Twelve patients with a histologically proven oral squamous cell carcinoma (OSCC) gargled a PARPi-FL solution for 60 s (15 mL, 100 nM, 250 nM, 500 nM, or 1000 nM), followed by gargling a clearing solution for 60 s. Fluorescence measurements of the lesion and surrounding oral mucosa were taken before PARPi-FL application, after PARPi-FL application, and after clearing. Blood pressure, oxygen levels, clinical chemistry, and CBC were obtained before and after tracer administration. RESULTS: PARPi-FL was well-tolerated by all patients without any safety concerns. When analyzing the fluorescence signal, all malignant lesions showed a significant differential in contrast after administration of PARPi-FL, with the highest increase occurring at the highest dose level (1000 nM), where all patients had a tumor-to-margin fluorescence signal ratio of >3. A clearing step was essential to increase signal specificity, as it clears unbound PARPi-FL trapped in normal anatomical structures. PARPi-FL tumor cell specificity was confirmed by ex vivo tabletop confocal microscopy. We have demonstrated that the fluorescence signal arose from the nuclei of tumor cells, endorsing our macroscopic findings. CONCLUSIONS: A PARPi-FL swish & spit solution is a rapid and non-invasive diagnostic tool that preferentially localizes fluorescent contrast to OSCC. This technique holds promise for the early detection of OSCC based on in vivo optical evaluation and targeted biopsy of suspicious lesions in the oral cavity. TRIAL REGISTRATION: Clinicaltrials.gov -NCT03085147, registered on March 21st, 2017.
Zeitschriftentitel:: Eur J Nucl Med Mol Imaging
Jahr:: 2021
Band / Volume:: 48
Heft / Issue:: 11
Seitenangaben Beitrag:: 3618-3630
Volltext / DOI:: doi:10.1007/s00259-021-05372-6
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/33954826
Print-ISSN:: 1619-7070
TUM Einrichtung:: Klinik und Poliklinik für Nuklearmedizin
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Nuklearmedizin (Prof. Weber)2021